Study shows similar outcomes with RIC and MAC in MDS

HSCT preparation
Photo by Chad McNeeley
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat myelodysplastic syndromes (MDS), regardless of the conditioning regimen they received. Rates of engraftment, graft-vs-host disease (GVHD), relapse, and survival were similar between patients who received reduced-intensity... [Read Article]

Model illustrates progression to MDS, AML

Induced pluripotent stem cells
Image by James Thomson
Researchers say they have created a model that shows the step-by-step progression from normal blood cells to acute myeloid leukemia (AML). The team generated induced pluripotent stem cell (iPSC) lines capturing disease stages that included preleukemia, low-risk myelodysplastic syndrome (MDS), high-risk MDS, and AML. The researchers then used... [Read Article]

Genetic profiling can guide HSCT in MDS, team says

Micrograph showing MDS

Genetic profiling can be used to determine which patients with myelodysplastic syndrome (MDS) are likely to benefit from allogeneic hematopoietic stem cell transplant (HSCT), according to research published in NEJM. Targeted sequencing of 129 genes revealed mutations that, after adjustment for clinical variables, were associated with shorter survival and/or relapse after HSCT. ... [Read Article]

Azathioprine may increase risk of MDS, AML

Azathioprine tablets

Results of a large, retrospective study suggest that taking azathioprine, a drug commonly used to treat autoimmune disease, may increase a person’s risk of developing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Researchers analyzed data on more than 40,000 patients with 27 common autoimmune diseases and found that azathioprine use was significantly... [Read Article]

Targeting disease stem cells in AML, MDS

Leukemia stem cells
Image by Robert Paulson

The cell surface molecule CD99 occurs more frequently than normal on stem cells responsible for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to research published in Science Translational Medicine. Building on this discovery, researchers designed anti-CD99 monoclonal antibodies (mAbs). In vitro and in vivo experiments ... [Read Article]